TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01.

On December 12, 2016, TRACON Pharmaceuticals, Inc. and 4350 La
Jolla Village LLC entered into a lease (the Lease) with respect
to the property located at 4350 La Jolla Village Drive, Suite
800, in San Diego, California (the Property). The Lease covers
approximately 10,458 square feet of general office space in the
Property and has an initial term of five years, with an option
for an additional five-year term. The Lease has an anticipated
commencement date of May 1, 2017 and an initial rental rate of
$3.13 per square foot, with annual increases of up to 4.5%
thereafter. If TRACON exercises the option for an additional
five-year term, the rental rate will be adjusted to the
then-prevailing market rate. The office space under the Lease
will serve as TRACONs new corporate headquarters, replacing the
Companys current facilities in San Diego, California.

The Lease is filed as Exhibit 99.1 to this report and the
description of the terms of the Lease is qualified in its
entirety by reference to such exhibit.

About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Recent Trading Information

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) closed its last trading session down -0.10 at 4.55 with 93,056 shares trading hands.